{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:49:09Z","timestamp":1790254149491,"version":"4.1.0"},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"61","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,28]]},"DOI":"10.18632\/oncotarget.22001","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T18:58:13Z","timestamp":1508871493000},"page":"104046-104056","source":"Crossref","is-referenced-by-count":39,"title":["Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response"],"prefix":"10.18632","volume":"8","author":[{"given":"Dwight H.","family":"Owen","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Konda","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Hemminger","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl R.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif R.Z.","family":"Abdel-Misih","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Dillhoff","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Sipos","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Kirschner","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha H.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"1","first-page":"749","article-title":"An update on gastroenteropancreatic neuroendocrine tumors","volume":"28","author":"Strosberg","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"449","author":"McNicol","year":"2006","journal-title":"Virchows Arch"},{"key":"3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Singh","year":"2015","journal-title":"Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Hahn","year":"1986","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Martinez","year":"2014","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Gress","year":"2009","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11605-007-0089-z","article-title":"Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned","volume":"11","author":"Shah","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Hammel","year":"2011","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Hoosen","year":"2011","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1634\/theoncologist.2015-0470","article-title":"The Role of Capecitabine\/Temozolomide in Metastatic Neuroendocrine Tumors","volume":"21","author":"Woltering","year":"2016","journal-title":"Oncologist"},{"key":"11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1023\/A:1011632713360","article-title":"Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282","volume":"12","author":"Haller","year":"2001","journal-title":"Ann Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Schadendorf","year":"2000","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Ludwin","year":"2005","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Fuchs","year":"2006","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Kulke","year":"2012","journal-title":"J Clin Oncol"},{"key":"16","first-page":"1461","article-title":"Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines","volume":"17","author":"Matsubara","year":"2007","journal-title":"Oncol Rep"},{"key":"17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience","volume":"71","author":"Lee","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Redston","year":"2009","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/bjc.2014.660","article-title":"O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents","volume":"112","author":"Scoazec","year":"2015","journal-title":"Br J Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1530\/erc-16-0147","article-title":"Analysis of potential response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors","volume":"23","author":"Strosberg","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1200\/jco.2005.23.16_suppl.4216","article-title":"Effective Treatment of Neuroendocrine Tumors with Capecitabine and Temozolomide","volume":"23","author":"Schreibman","year":"2005","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Kvols","year":"2011","journal-title":"Cancer"},{"key":"23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/erc-16-0117","article-title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors","volume":"23","author":"Ruszniewski","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2147\/ott.s72155","article-title":"Profile of capecitabine\/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors","volume":"9","author":"Saif","year":"2016","journal-title":"Onco Targets Ther"},{"key":"25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/jco.2014.32.3_suppl.179","article-title":"Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors","volume":"32","author":"Chabot","year":"2014","journal-title":"J Clin Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2217\/fon.14.302","article-title":"Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature","volume":"11","author":"Fouad","year":"2015","journal-title":"Future Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000430816","article-title":"Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects","volume":"101","author":"Fazio","year":"2015","journal-title":"Neuroendocrinology"},{"key":"28","doi-asserted-by":"crossref","first-page":"e15169","DOI":"10.1200\/jco.2014.32.15_suppl.e15169","article-title":"MGMT immunohistochemistry (IHC) and exclusion of pancreatic NET (PanNET) patients from treatment with temozolomidebased therapy","volume":"32","author":"Zhang","year":"2014","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1200\/jco.2015.33.15_suppl.4099","article-title":"Identification of response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors","volume":"33","author":"Ghayouri","year":"2015","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1078-0432.ccr-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Skogseid","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T18:46:11Z","timestamp":1596739571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":30,"journal-issue":{"issue":"61","published-print":{"date-parts":[[2017,11,28]]}},"alternative-id":["22001","29262620"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.22001","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,24]]}}}